Live vaccinations for infants exposed to maternal infliximab in utero and via breast milk - the need for nuanced decision making
BMJ Open Gastroenterol
.
2022 Oct;9(1):e001029.
doi: 10.1136/bmjgast-2022-001029.
Authors
Christian Philipp Selinger
1
,
Klaartje Bel Kok
2
,
Jimmy K Limdi
3
4
,
Alexandra Kent
5
,
Rachel Cooney
6
,
Catherine Nelson-Piercy
7
Affiliations
1
Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, Leeds, UK christian.selinger@web.de.
2
Department of Gastroenterology, Barts Health NHS Trust, London, UK.
3
The Pennine Acute Hospitals NHS Trust Gastroenterology, Manchester, UK.
4
The University of Manchester, Manchester, UK.
5
Gastroenterology, King's College Hospital NHS Foundation Trust, London, London, UK.
6
Department of Gastroenterology, University Hospitals Birmingham NHS Trust, Birmingham, West Midlands, UK.
7
Guy's and St Thomas' Hospitals NHS Trust, London, London, UK.
PMID:
36216381
PMCID:
PMC9557327
DOI:
10.1136/bmjgast-2022-001029
No abstract available
Keywords:
BREAST FEEDING; BREAST MILK; INFLAMMATORY BOWEL DISEASE.
MeSH terms
Breast Feeding*
Decision Making
Female
Humans
Infant
Infliximab / adverse effects
Milk, Human*
Vaccination / adverse effects
Substances
Infliximab